Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years

Table 2 Variables associated with improvement of alanine aminotransferase < 30 (male)/19 (female), aspartate aminotransferase to platelet ratio index < 0.5, and fibrosis-4 < 1.45 at switching week 144

	ALT < 30/19			APRI < 0.5			FIB-4 < 1.45
	Yes	No	P value	Yes	No	P value	Yes	No	P value
Gender (male)	20/24 (83.3)	15/29 (51.7)	0.016	23/24 (95.8)	28/29 (96.6)	0.891	16/24 (66.7)	15/29 (51.7)	0.272
Age > 50 years	23/35 (65.7)	12/18 (66.7)	0.945	34/35 (97.1)	17/18 (94.4)	0.625	17/18 (94.4)	14/35 (40)	0.001
BMI > 25 kg/m2	11/17 (64.7)	24/36 (66.7)	0.888	35/36 (97.2)	16/17 (94.1)	0.58	16/17 (94.1)	15/36 (41.7)	0.001
Cirrhosis	4/8 (50)	31/45 (68.9)	0.299	6/8 (75)	45/45 (100)	0.001	2/8 (25)	29/45 (64.4)	0.037
Pre-Rx spleen size > 12 cm	2/4 (50)	33/48 (68.8)	0.442	2/4 (50)	48/48 (100)	0.001	1/4 (25)	30/48 (62.5)	0.142
Platelets < 120 × 109/L Rx wk 24	1/4 (25)	33/46 (71.7)	0.078	2/4 (50)	46/46 (100)	0.001	1/4 (25)	29/46 (63)	0.221
APRI < 0.5 at Rx wk 24	33/45 (73.3)	1/5 (20)	0.027	45/45 (100)	3/5 (60)	0.001	29/45 (64.4)	1/5 (20)	0.106
FIB-4 < 1.45 at Rx wk 24	22/31 (71)	12/19 (63.1)	0.399	31/31 (100)	17/19 (89.5)	0.156	27/31 (87.1)	3/19 (15.8)	0.001
ALT < 30/19 U/L at Rx wk 24	28/37 (75.7)	7/16 (43.8)	0.024	36/37 (97.2)	15/16 (93.8)	0.534	20/37 (54)	11/16 (68.8)	0.319
AST < 30/19 U/L at Rx wk 24	25/34 (73.5)	10/19 (52.6)	0.123	34/34 (100)	17/19 (89.5)	0.054	23/34 (67.6)	8/19 (42.1)	0.07
ALT < 35/25 at Rx wk 24	33/45 (73.3)	2/8 (25)	0.008	44/45 (97.8)	7/8 (87.5)	0.16	25/45 (55.6)	6/8 (75)	0.304
AST < 35/25 at Rx wk 24	34/49 (69.4)	1/4 (25)	0.071	48/49 (97.9)	3/4 (75)	0.021	28/49 (57.1)	3/4 (75)	0.486

BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; APRI: Aspartate aminotransferase to platelet ratio index; FIB-4: Fibrosis-4; SWE: Shear wave elastography.